Skip to content
Medical Health Aged Care

Victorians Gain Access to Cutting-Edge Precision Cancer Therapies Thanks to Landmark $10M Donation

Monash University 3 mins read

Cabrini Health, in partnership with Monash University, is set to transform cancer care for Victorians, thanks to a game-changing $10 million donation. This landmark funding will establish a cutting-edge genomic testing program at Cabrini providing personalised, precision treatment for up to 2,000 additional patients annually.

 

The generous $10 million donation from the PMF Foundation was inspired by the personal experience of a patient under the care of Professor Gary Richardson OAM, Group Director of Cabrini Research and medical oncologist at Cabrini Hospital, who also holds a professorial appointment at Monash University.

 

PMF Foundation Managing Director, Nicola Clyne, said: "The patient personally credited Professor Richardson and the Cabrini team with significantly prolonging their life using genomic profiling throughout their treatment. Their vision was to make a pledge that enables more people with cancer to extend their lives in the same way.”

 

Professor Richardson, leveraging his oncology and genomic research expertise, will lead this transformative initiative at Cabrini. He said: "Through broader, more comprehensive genomic testing panels, our clinicians will be able to precisely identify and target the unique genetic drivers of each patient's cancer - a crucial step in delivering the most effective, tailored care."

 

"Currently, whole genomic testing requests can take up to six months with patient costs up to $4000. Thanks to this generous donation, we aim to reduce this to just weeks by creating the capacity to serve more Victorians in Melbourne's south-east corridor and beyond," adds Professor Richardson.

 

The $10m in funding will be allocated to Cabrini in partnership with Monash over the next five years, establishing the infrastructure to screen over 2,000 additional Victorians genomically per year (1,000 during the first year of operation). The program is expected to begin treating patients in 2025, including public patients who may have previously been unable to afford such specialised testing.

 

The donation will support Cabrini’s appointment of a Monash University affiliated Chair of Genomics and the creation of a dedicated genomics laboratory. This will empower Cabrini Research to expand its precision cancer treatment clinical trials.

 

"If patients enter a system with closer monitoring and access to genomic sequencing, it's proven they do much better," Professor Richardson said. "This donation represents a significant step forward in the fight against cancer."


Professor Richardson is a leading expert in rare cancers which disproportionately contribute to cancer-related deaths. He emphasises that the data generated through this genomic profiling initiative will improve treatments for future generations.

 

For example, the insights gained could unlock a deeper understanding of the complex signalling pathways responsible for triple-negative breast cancer, an aggressive form of the disease that lacks targeted therapies. Similarly, the program will generate data that could lead to targeted therapies for High-Grade Serous Ovarian Carcinoma - a prominent type of ovarian cancer with a low survival rate.

 

- ends –

Notes to editors: About the Cabrini Monash Partnership

Cabrini Health and Monash University’s longstanding partnership provides the opportunity to deliver the most advanced, evidence-based, and patient-centred care. By combining Cabrini's clinical expertise with Monash's academic excellence, the institutions can together potentially unlock transformative breakthroughs that will improve outcomes for patients across Victoria. Cabrini’s partnership with Monash University research is strongly collaborative and strengthened by a ‘bench to bedside' approach.

Thanks to a generous $10 million donation made by a patient in 2024, the two institutions will establish a cutting-edge genomic testing program over the next five years. This program will leverage the latest advancements in genomic medicine to provide personalised, precision treatment, revolutionising the way healthcare is delivered.

 

For media enquiries please contact:

 

Cabrini Health

Lisa Webbe – Communications and Media Manager

media@cabrini.com.au

T: +61 (0) 436 928 801

 

Monash University

Cheryl Critchley – Media and Communications Manager (medical)
E:
cheryl.critchley@monash.edu

T: +61 (0) 477 571 442

More from this category

  • Disability, Medical Health Aged Care
  • 20/12/2024
  • 17:36
Kuremara

Kuremara to Open a State-of-the-Art Activity Center in Milton, QLD, in January 2025

Kuremara, a trusted and leading NDIS-registered provider in Australia, is excited to announce the opening of its newest facility—a cutting-edge activity center in Milton,…

  • Contains:
  • Legal, Medical Health Aged Care
  • 20/12/2024
  • 17:29
JGA Saddler

BREAKING NEWS: Australian law firm takes on Johnson & Johnson for selling Australians ineffective medicine

Vision available: Lawyer and doctor VNR, editorial photos and radio grabs included can be found in this SharePoint File In-person lawyer interviews available by…

  • Contains:
  • Medical Health Aged Care
  • 20/12/2024
  • 12:01
NDARC/UNSW

ADHD drug shows promise for treating methamphetamine dependence, landmark Australian study shows

A prescription medication used to treat attention deficit hyperactivity disorder (ADHD) could be repurposed as the first pharmacotherapy for people with methamphetamine dependence, according to a study published in Addiction. Results from the landmark ‘LiMA’ trial show that thepsychostimulant lisdexamfetamine can drastically reduce the need to use methamphetamine among those who are dependent on the illicit drug. Lead author and addiction medicine specialist Professor Nadine Ezard, who is Director of the National Centre for Clinical Research on Emerging Drugs (NCCRED), said the results were promising. "There is currently no pharmacotherapy approved for treating methamphetamine dependence," Professor Ezard said. “While further…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.